Page 1

Pfizer PFIZER REPORTS SECOND - QUARTER 2021 RESULTS Second - Quarter 2021 Revenues of $ 19.0 Billion , Reflecting 86 % Operational Growth ; Excluding BNT162b2¹ ) , Revenues Grew 10 % Operationally to $ 11.1 Billion The 10 % Operational Growth Excluding BNT 162b2¹ ) in Second - Quarter 2021 Builds on the 6 % Operational Growth Delivered by the Comparable Business in Second - Quarter 2020 Second - Quarter 2021 Reported Diluted EPS ( 2 ) of $ 0.98 , Adjusted Diluted EPS of $ 1.07 Raises Full - Year 2021 Guidance ( 4 ) for Revenues to a Range of $ 78.0 to $ 80.0 Billion and Adjusted Diluted EPS ) to a Range of $ 3.95 to $ 4.05 , Reflecting Updates to the Outlook for Pfizer's Business , Both Including and Excluding BNT162b2 ( ¹ ) Now Anticipates 2021 Revenues of Approximately $ 33.5 Billion for BNT162b2 ( ¹ ) , Reflecting 2.1 Billion Doses Expected to be Delivered in 2021 Under Signed Contracts as of Mid - July 2021 Raises Guidance Ranges Excluding BNT162b2 ( ¹ ) for Revenue by $ 400 Million and Adjusted Diluted EPS ( 3 ) by $ 0.05 100 % Efficacy Observed in Phase 2b Trial of RSV Adult Vaccine Candidate ; Provides New Data Updates on its COVID - 19 Vaccine Booster and Oral COVID - 19 Antiviral Programs As Part of a Broader Review of 8 Potentially First - in - Class Compounds NEW YORK , NY , Wednesday , July 28 , 2021 – Pfizer Inc. ( NYSE : PFE ) reported financial results for second quarter 2021 and raised 2021 guidance ( 4 ) for revenues and Adjusted diluted EPS ) driven by its updated expectations for contributions to 2021 performance from both BNT162b2 , the Pfizer - BioNTech SE ( BioNTech ) COVID - 19 vaccine , as well as its business excluding BNT162b2 ( ¹ ) . Additionally , Pfizer published this morning on its website the second - quarter 2021 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to its R & D pipeline . EXECUTIVE COMMENTARY Dr. Albert Bourla , Chairman and Chief Executive Officer , stated : " The second quarter was remarkable in a number of ways . Most visibly , the speed and efficiency of our efforts with BioNTech to help vaccinate the world against COVID - 19 have been unprecedented , with now more than a billion doses of BNT162b2 having been delivered globally . In addition , we are equally proud of the second - quarter performance of our business excluding BNT162b2 ( ¹ ) , which posted 10 % operational revenue growth . Looking forward , we remain highly confident in our ability to achieve at least a 6 % compound annual growth rate through 2025 and intend to build upon our recent successes by continuing to follow the science , trust in our people and remain focused on delivering breakthroughs for the patients we serve . " - 1